Briefing
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
EuroFlow 2-tube 8-color NGF with acquisition of ≥10^7 cells; LOD <2×10^-6 and LOQ <5×10^-6. In 110 BM samples from patients in VGPR or CR, MRD-positive rate was 47% by NGF vs 34% by conventional 8-color flow (P=0.003); 25% of conventional MRD-negative cases were NGF-positive. NGF MRD-negative vs MRD-positive CR patients had longer PFS (75% PFS not reached vs 7 months; P=0.02).
- Design: assay
- n: 110
- Assay: EuroFlow NGF, bone marrow